Close Menu

NEW YORK (360Dx) – Roche said today it has garnered US Food and Drug Administration approval for its Ventana PD-L1 (SP142) Assay as a companion diagnostic for identifying which triple-negative breast cancer patients have increased PD-L1 expression on tumor-infiltrating immune cells and are more likely to respond to the immunotherapy Tecentriq (atezolizumab) plus chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.